Literature DB >> 20176284

International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009.

Victor D Rosenthal1, Dennis G Maki, Silom Jamulitrat, Eduardo A Medeiros, Subhash Kumar Todi, David Yepes Gomez, Hakan Leblebicioglu, Ilham Abu Khader, María Guadalupe Miranda Novales, Regina Berba, Fernando Martín Ramírez Wong, Amina Barkat, Osiel Requejo Pino, Lourdes Dueñas, Zan Mitrev, Hu Bijie, Vaidotas Gurskis, S S Kanj, Trudell Mapp, Rosalía Fernández Hidalgo, Nejla Ben Jaballah, Lul Raka, Achilleas Gikas, Altaf Ahmed, Le Thi Anh Thu, María Eugenia Guzmán Siritt.   

Abstract

We report the results of the International Infection Control Consortium (INICC) surveillance study from January 2003 through December 2008 in 173 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study, using Centers for Disease Control and Prevention (CDC) US National Healthcare Safety Network (NHSN; formerly the National Nosocomial Infection Surveillance system [NNIS]) definitions for device-associated health care-associated infection, we collected prospective data from 155,358 patients hospitalized in the consortium's hospital ICUs for an aggregate of 923,624 days. Although device utilization in the developing countries' ICUs was remarkably similar to that reported from US ICUs in the CDC's NHSN, rates of device-associated nosocomial infection were markedly higher in the ICUs of the INICC hospitals: the pooled rate of central venous catheter (CVC)-associated bloodstream infections (BSI) in the INICC ICUs, 7.6 per 1000 CVC-days, is nearly 3-fold higher than the 2.0 per 1000 CVC-days reported from comparable US ICUs, and the overall rate of ventilator-associated pneumonia (VAP) was also far higher, 13.6 versus 3.3 per 1000 ventilator-days, respectively, as was the rate of catheter-associated urinary tract infection (CAUTI), 6.3 versus 3.3 per 1000 catheter-days, respectively. Most strikingly, the frequencies of resistance of Staphylococcus aureus isolates to methicillin (MRSA) (84.1% vs 56.8%, respectively), Klebsiella pneumoniae to ceftazidime or ceftriaxone (76.1% vs 27.1%, respectively), Acinetobacter baumannii to imipenem (46.3% vs 29.2%, respectively), and Pseudomonas aeruginosa to piperacillin (78.0% vs 20.2%, respectively) were also far higher in the consortium's ICUs, and the crude unadjusted excess mortalities of device-related infections ranged from 23.6% (CVC-associated bloodstream infections) to 29.3% (VAP). 2010 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20176284     DOI: 10.1016/j.ajic.2009.12.004

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  90 in total

1.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009.

Authors:  A R Caffrey; K L LaPlante
Journal:  Infection       Date:  2011-12-13       Impact factor: 3.553

2.  Impact of a multidimensional infection control strategy on central line-associated bloodstream infection rates in pediatric intensive care units of five developing countries: findings of the International Nosocomial Infection Control Consortium (INICC).

Authors:  V D Rosenthal; B Ramachandran; W Villamil-Gómez; A Armas-Ruiz; J A Navoa-Ng; L Matta-Cortés; M Pawar; A Nevzat-Yalcin; M Rodríguez-Ferrer; R D Yıldızdaş; A Menco; R Campuzano; V D Villanueva; L F Rendon-Campo; A Gupta; O Turhan; N Barahona-Guzmán; O O Horoz; P Arrieta; J M Brito; M C V Tolentino; Y Astudillo; N Saini; N Gunay; G Sarmiento-Villa; E Gumus; A Lagares-Guzmán; O Dursun
Journal:  Infection       Date:  2012-02-28       Impact factor: 3.553

3.  New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans.

Authors:  Walid F Elkhatib; Pamela S Hair; Julius O Nyalwidhe; Kenji M Cunnion
Journal:  J Med Microbiol       Date:  2015-04       Impact factor: 2.472

Review 4.  Antibiotic use and emerging resistance: how can resource-limited countries turn the tide?

Authors:  Lisa M Bebell; Anthony N Muiru
Journal:  Glob Heart       Date:  2014-10-31

5.  Structural Basis for Enhancement of Carbapenemase Activity in the OXA-51 Family of Class D β-Lactamases.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Nichole K Stewart; Hilary Frase; Marta Toth; Katherine A Kantardjieff; Sergei Vakulenko
Journal:  ACS Chem Biol       Date:  2015-06-12       Impact factor: 5.100

6.  Evaluation of phenotypic detection methods for metallo-β-lactamases (MBLs) in clinical isolates of Pseudomonas aeruginosa.

Authors:  S Peter; A Lacher; M Marschal; F Hölzl; M Buhl; I Autenrieth; M Kaase; M Willmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-23       Impact factor: 3.267

7.  Influence of tracheostomy on the incidence of catheter-related bloodstream infection in the catheterization of jugular vein by posterior access.

Authors:  L Lorente; A Jiménez; I Roca; M M Martín; M L Mora
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-08       Impact factor: 3.267

8.  Socioeconomic impact on device-associated infections in limited-resource neonatal intensive care units: findings of the INICC.

Authors:  V D Rosenthal; P Lynch; W R Jarvis; I A Khader; R Richtmann; N B Jaballah; C Aygun; W Villamil-Gómez; L Dueñas; T Atencio-Espinoza; J A Navoa-Ng; M Pawar; M Sobreyra-Oropeza; A Barkat; N Mejía; C Yuet-Meng; A Apisarnthanarak
Journal:  Infection       Date:  2011-07-06       Impact factor: 3.553

9.  Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 11 adult intensive care units from 10 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC).

Authors:  H Leblebicioglu; A N Yalcin; V D Rosenthal; I Koksal; F Sirmatel; S Unal; H Turgut; D Ozdemir; G Ersoz; C Uzun; S Ulusoy; S Esen; F Ulger; A Dilek; H Yilmaz; O Turhan; N Gunay; E Gumus; O Dursun; G Yýlmaz; S Kaya; H Ulusoy; M Cengiz; L Yilmaz; G Yildirim; A Topeli; S Sacar; H Sungurtekin; D Uğurcan; M F Geyik; A Şahin; S Erdogan; A Kaya; N Kuyucu; B Arda; F Bacakoglu
Journal:  Infection       Date:  2013-01-26       Impact factor: 3.553

10.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.